COVID-19 and its impact have demonstrated that change can be rapid, disruptive, and non-negotiable. This is especially relevant to enterprise risk management, where the challenge can be summed up in one word: recalibration. Many financial institutions have been investing in model-driven analysis and data-anchored approaches. We know that the models themselves must adapt as situations change. But what about the processes and policy governance that surround these models?

Go ahead, search the interwebs. There are more posts and articles on “The Ten Commandments of Test Automation” than you can shake a test case at. Go ahead…I’ll wait. Welcome back! To set the stage, I have not read any of those articles. Well, more accurately, I’ve not read any of them recently; most of them I’ve not read at all. I probably read one or two of them in the “before times,” but I don’t remember any of the specific commandments.

For life sciences organizations today, COVID-19 and an increasingly complex regulatory landscape are spurring an urgent need to launch new applications–fast. Yet a number of challenges stand in the way, including complex business processes, concerns about data security and integrity, and even just knowing where to begin on the right tech solution to put in place.

The COVID-19 pandemic has forced government organizations to reassess their strategies, plans, and aspirations for digital transformation. Despite this uncertainty, IT leaders must quickly identify and act on strategies and plans that lead to positive outcomes. In many cases, governments will expand the role of digital technologies in service and program delivery.

Last week, our team at Katalon Studio partnered with Applitools to present a webinar: Top 5 Features to Look for in a Codeless Automation Solution. With the rise in demands for QualityatSpeed products, there’s no denying the benefit of automation testing software has on product development cycles: they shorten the release cycle, and fast to match the tech industry’s ever-changing nature with developments in the testing industry itself.

In the wake of the COVID-19 pandemic, many life sciences organizations are seeking efficiency and control over the regulatory process more than ever before. There is an increased urgency for speed, accuracy, and simplified processes in the Regulatory Information Management (RIM) space, and to prioritize projects that will quickly deliver the most patient value.